NCT06129851 - Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

October 23, 2025

Study Completion Date

October 23, 2026

Conditions

Stage IIC Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

RADIATION

Brachytherapy

Undergo brachytherapy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Dual X-ray Absorptiometry

Undergo DEXA scan

RADIATION

External Beam Radiation Therapy

Undergo external beam radiation therapy

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

PSMA PET Scan

Undergo PSMA PET

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Relugolix

Given PO

Trial Locations (1)

66160

University of Kansas Cancer Center, Kansas City

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Kansas Medical Center

OTHER